Abstract
Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were 21 (67.7%); negative hENT1 staining patients were 10 (32.3%). Statistical analysis revealed no association between baseline characteristics, toxicities and tumor response to gemcitabine and hENT1 levels. In the univariate analysis, HENT1 expression was significantly correlated with time to progression (TTP) (p=0.0394; HR 2.902, 95%CI 1.053-7.996). The median TTP was 6.33 versus 2.83 months, respectively in patients with positive versus negative hENT1 staining. Moreover, patients with positive hENT1 expression showed a longer median overall survival when compared with patients with low hENT1 expression (14 versus 7 months, respectively), but this difference did not reach the statistical significance (p=0.128). Conclusions: Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in patients with advanced BTC.
Keywords: Biliary tract cancer, gemcitabine, hENT1, predictive factor, tumors, surgical, radiation, oncologists, prognosis, cytotoxic agents, optimal chemotherapeutic regimen, pyrimidine analogue, hematopoietic progenitor cells, pancreatic cancers, WHO guidelines, magnetic resonance imaging (MRI), tumour lesions, xylene baths, target antigen, pathologists, lymphocytes, staining, gall bladder, hematologic, dichotomized, extrahepatic biliary tract, oxaliplatin, toxicities, epithelial lining, gallbladder, bile ducts, heterogeneity
Current Cancer Drug Targets
Title: Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)
Volume: 11 Issue: 1
Author(s): R. Lai, G. Tonini, A. Falcone, J. Mackey, A. Russo, M. Caraglia, L. Chiusa, A. Giacobino, S. Rizzo, D. Santini, G. G. Baldi, V. Catalano, A. D. Manazza, E. Vasile, C. E. Cass, B. Vincenzi and G. Schiavon
Affiliation:
Keywords: Biliary tract cancer, gemcitabine, hENT1, predictive factor, tumors, surgical, radiation, oncologists, prognosis, cytotoxic agents, optimal chemotherapeutic regimen, pyrimidine analogue, hematopoietic progenitor cells, pancreatic cancers, WHO guidelines, magnetic resonance imaging (MRI), tumour lesions, xylene baths, target antigen, pathologists, lymphocytes, staining, gall bladder, hematologic, dichotomized, extrahepatic biliary tract, oxaliplatin, toxicities, epithelial lining, gallbladder, bile ducts, heterogeneity
Abstract: Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were 21 (67.7%); negative hENT1 staining patients were 10 (32.3%). Statistical analysis revealed no association between baseline characteristics, toxicities and tumor response to gemcitabine and hENT1 levels. In the univariate analysis, HENT1 expression was significantly correlated with time to progression (TTP) (p=0.0394; HR 2.902, 95%CI 1.053-7.996). The median TTP was 6.33 versus 2.83 months, respectively in patients with positive versus negative hENT1 staining. Moreover, patients with positive hENT1 expression showed a longer median overall survival when compared with patients with low hENT1 expression (14 versus 7 months, respectively), but this difference did not reach the statistical significance (p=0.128). Conclusions: Therefore, hENT1 may be a relevant predictive marker of benefit from gemcitabine-based therapies in patients with advanced BTC.
Export Options
About this article
Cite this article as:
Lai R., Tonini G., Falcone A., Mackey J., Russo A., Caraglia M., Chiusa L., Giacobino A., Rizzo S., Santini D., G. Baldi G., Catalano V., D. Manazza A., Vasile E., E. Cass C., Vincenzi B. and Schiavon G., Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC), Current Cancer Drug Targets 2011; 11 (1) . https://dx.doi.org/10.2174/156800911793743600
DOI https://dx.doi.org/10.2174/156800911793743600 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Adrenergic System in Gastrointestinal Cancers
Current Cancer Therapy Reviews Recent Advances in Epitope Design for Immunotherapy of Cancer
Recent Patents on Anti-Cancer Drug Discovery Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy
Recent Patents on Anti-Cancer Drug Discovery Developmental Expression and Dysregulation of miR-146a and miR-155 in Down's Syndrome and Mouse Models of Down's Syndrome and Alzheimer's Disease
Current Alzheimer Research Cancer Metastasis as Disrupted Developmental Phenotype
Current Genomics Impact of New Technologies on Pharmacogenomics
Current Pharmacogenomics and Personalized Medicine Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine Cancer Therapy-Induced Residual Bone Marrow Injury: Mechanisms of Induction and Implication for Therapy
Current Cancer Therapy Reviews Biomarkers for Systemic Therapy in Ovarian Cancer
Current Cancer Drug Targets Genetic Predisposition to Neonatal Tumors
Current Pediatric Reviews Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry Antineoplastic Activity, Structural Modification, Synthesis and Structure-activity Relationship of Dammarane-type Ginsenosides: An Overview
Current Organic Chemistry Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Mitochondrial DNA Mutations in Cancer: A Review
Current Topics in Medicinal Chemistry The Role of the Immune System in the Pathogenesis of Hypertension
Current Hypertension Reviews Pro-Oncogenic Cell Signaling Machinery as a Target for Oncolytic Viruses
Current Pharmaceutical Biotechnology Current Treatment for Cervical Cancer: An Update
Anti-Cancer Agents in Medicinal Chemistry Oligodendrocyte Development and Myelination in Neurodevelopment: Molecular Mechanisms in Health and Disease
Current Pharmaceutical Design Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry A3 Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry